Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Chiral Amide. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN113735756A details a high-yield Rh-catalyzed method for chiral 3,3-disubstituted isoindolinones, offering significant cost reduction and supply chain reliability for pharmaceutical intermediates.
Patent CN118638038B reveals novel chiral isothiourea catalysis for high-purity indole amides. Enables cost reduction and scalable supply chain for pharmaceutical intermediates manufacturing.
Patent CN113735756A details a novel Rh-catalyzed [4+1] cyclization for high-purity chiral isoindolinones, offering significant cost reduction in API manufacturing.
Patent CN113735756A details a novel Rh-catalyzed method for chiral 3,3-disubstituted isoindolinones, offering high enantioselectivity and mild conditions for pharmaceutical manufacturing.
Patent CN113735756A details a high-yield Rh-catalyzed method for chiral 3,3-disubstituted isoindolinones, offering cost-effective pharma intermediate manufacturing.
Patent CN118638038B delivers high-yield synthesis of N-axis chiral indole amides with exceptional enantioselectivity enabling cost reduction in pharmaceutical manufacturing and robust supply chain solutions.
Patent CN110615811A enables high-purity chiral ligand synthesis via crystallization method eliminating column chromatography thus reducing manufacturing costs and improving supply chain reliability.
Recent patent reveals chiral isothiourea-catalyzed synthesis of N-axis chiral indole amides with mild conditions and high enantioselectivity enabling cost reduction and reliable supply for pharmaceutical intermediates.
Solve chiral purity challenges in halichondrin synthesis with 99.7% ee and 92% yield. Reduce impurity removal burden for Eribulin mesylate production. CDMO expertise for scalable manufacturing.
Discover a scalable chiral ligand synthesis method with 80%+ yield, eliminating column chromatography to cut costs and environmental impact. Ideal for API manufacturing.
Discover a scalable, high-yield synthesis of N-axis chiral indole amides with >95% ee and potent Hep G2 cytotoxicity. Reduce R&D costs and supply chain risks with our CDMO expertise.